Clear Vision Study (NCT01970267) | Clinical Trial Compass
CompletedNot Applicable
Clear Vision Study
Canada35 participantsStarted 2013-10
Plain-language summary
Vitreous floaters are tiny, cloudy, clumps of cells that appear in the otherwise clear fluid (vitreous) that fills the back 3/4 of the eye. Floaters are commonly caused by eye conditions such as posterior vitreous detachment (PVD), vitreous syneresis and asteroid hyalosis. While these symptoms are considered physiological in nature, they can be of considerable inconvenience to many patients which affect essential activities. The investigators wish to assess the safety and efficacy of floater treatment in patients with highly symptomatic floaters using an FDA approved nanosecond infrared yttrium aluminum garnet (YAG) lasers.
Who can participate
Age range
19 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Have been diagnosed with symptomatic floaters lasting more than 2 months
* Willing to proceed with intervention
* Be able to provide informed consent
* Diagnosed with Posterior Vitreous Detachment
* Accept a 1% risk of complications
Exclusion Criteria:
* Less than 19 years of age
* Is a high myope (greater than -6 diopters)
* Has monocular vision
* Diagnosed with asteroid hyalosis
* Diagnosed with acute on-set of floaters (less than two months and may clear spontaneously)
* Has corneal or lenticular opacities or any media opacity which may interfere with treatment
* Has any concomitant ocular disease or pathology
* Has elevated intraocular pressure (IOP) or on IOP lowering medication
* Has floaters that are deemed to require more than five treatment sessions, where surgical intervention is the best treatment course
* Has floaters inaccessible with current lasers and lenses
* Has floaters located less than 2mm from the crystalline lens or the retina
* Found to have retinal tears or retinal detachment on initial examination or has had a history of retinal detachment repair within the last two years
* Has psychiatric problems that may recur or worsen
* Incapacity to provide informed consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Efficacy of the laser treatment measured by the improvement of visual acuity and floater specific Visual Function Questionnaire (VFQ).
Timeframe: after the last treatment session (approximately 5 days)